Activated fibroblast growth factor receptor 3 is an oncogene that contributes to tumor progression in multiple myeloma

Blood

Volumn 97, Issue 3, 2001, Pages 729-736

  Chesi, Marta ^b   Brents, Leslie A ^b   Ely, Sarah A ^b   Bais, Carlos ^b   Robbiani, Davide F ^b   Mesri, Enrique A ^b   Kuehl, W Michael ^b   Bergsagel, P Leif ^a  

^a Department of Obstetrics Gynecology   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

FIBROBLAST GROWTH FACTOR RECEPTOR; IMMUNOGLOBULIN HEAVY CHAIN;

ARTICLE; CHROMOSOMAL LOCALIZATION; CHROMOSOME TRANSLOCATION; DIMERIZATION; GENE ACTIVATION; GENE TARGETING; HUMAN; HUMAN CELL; MONONUCLEAR CELL; MULTIPLE MYELOMA; ONCOGENE K RAS; POINT MUTATION; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN FAMILY; THANATOPHORIC DWARFISM; TUMOR GROWTH;

EID: 0035254612     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V97.3.729     Document Type: Article

References (49)

1. Promiscuous translocations into IgH switch regions in multiple myeloma
2. Frequent dysregulation of the c-maf proto-oncogene at 16q23 by translocation to an Ig locus in multiple myeloma
3. Insertion of excised IgH switch sequences causes overexpression of cyclin D1 in a myeloma tumor cell
4. Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma: Association with increased expression and activating mutation of fibroblast growth factor receptor 3
5. Detection of t(4;14)(p16.3;q32) chromosomal translocation in multiple myeloma by double-color fluorescent in situ hybridization
6. High incidence of translocations t(11;14)(q13;q32) and t(4;14)(p16;q32) in patients with plasma cell malignancies
7. The t(4;14) translocation in myeloma dysregulates both FGFR3 and a novel gene, MMSET, resulting in IgH/MMSET hybrid transcripts
8. Unique expression pattern of the FGF receptor 3 gene during mouse organogenesis
9. Signal transduction pathway of human fibroblast growth factor receptor 3: Identification of a novel 66-kDa phosphoprotein
10. Mutations in the transmembrane domain of FGFR3 cause the most common genetic form of dwarfism, achondroplasia
11. Graded activation of fibroblast growth factor receptor 3 by mutations causing achondroplasia and thanatophoric dysplasia
12. FGFR activation in skeletal disorders: Too much of a good thing
13. Activation of Stat1 by mutant fibroblast growth-factor receptor in thanatophoric dysplasia type II dwarfism
14. FGF signaling inhibits chondrocyte proliferation and regulates bone development through the STAT-1 pathway
15. Fibroblast growth factor receptor 3 mutations promote apoptosis but do not alter chondrocyte proliferation in thanatophoric dysplasia
16. Ectopic expression of fibroblast growth factor receptor 3 promotes myeloma cell proliferation and prevents apoptosis
17. Diverse karyotypic abnormalities of the c-myc locus associated with c-myc dysregulation and tumor progression in multiple myeloma
18. Characterization of a human plasmacytoma line
19. Establishment of a CD45-positive immature plasma cell line from an aggressive multiple myeloma with high serum lactate dehydrogenase
20. Characterization of new IgG lambda myeloma plasma cell line (EJM): A further tool in the investigation of the biology of multiple myeloma
21. Two distinct human myeloma cell lines originating from one patient with myeloma
22. Establishment and characterization of a human stroma-dependent myeloma cell line (MM5.1) and its stroma-independent variant (MM5.2)
23. Selective expression of one c-myc allele in two human myeloma cell lines
24. Multiple independent activations of the neu oncogene by a point mutation altering the transmembrane domain of p185
25. Stop codon FGFR3 mutations in thanatophoric dwarfism type 1
26. FGFR3 gene mutations associated with human skeletal disorders occur rarely in multiple myeloma
27. Multiple myeloma: Increasing evidence for a multistep transformation process
28. Introduction of an activated N-ras oncogene alters the growth characteristics of the interleukin 6-dependent myeloma cell line ANBL6
29. Ras oncogene mutation in multiple myeloma
30. K-sam, an amplified gene in stomach cancer, is a member of the heparin-binding growth factor receptor genes
31. BEK and FLG, two receptors to members of the FGF family, are amplified in subsets of human breast cancers
32. Aberrant expression of type I fibroblast growth factor receptor in human pancreatic adenocarcinomas
33. Differential expression of two fibroblast growth factor-receptor genes is associated with malignant progression in human astrocytomas
34. Ligand-independent activation of tyrosine kinase in fibroblast growth factor receptor 1 by fusion with beta-galactosidase
35. Activation of FGF receptors by mutations in the transmembrane domain
36. Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas
37. G-protein-coupled receptor of Kaposi's sarcoma-associated herpesvirus is a viral oncogene and angiogenesis activator
38. Profound ligand-independent kinase activation of fibroblast growth factor receptor 3 by the activation loop mutation responsible for a lethai skeletal dysplasia, thanatophoric dysplasia type II
39. Role of FGFs and FGF receptors in human carcinogenesis
40. The FGF family of growth factors and oncogenes
41. The t(6; 8)(q27;p11) translocation in a stem cell myeloproliferative disorder fuses a novel gene, FOP, to fibroblast growth factor receptor 1
42. FGFR1 is fused with a novel zinc-finger gene, ZNF198, in the t(8;13) leukaemia/lymphoma syndrome
43. Constitutive activation of fibroblast growth factor receptor 3 by the transmembrane domain point mutation found in achondroplasia
44. Enhanced signaling and morphological transformation by a membrahe-localized derivative of the fibroblast growth factor receptor 3 kinase domain
45. The transmembrane mutation G380R in fibroblast growth factor receptor 3 uncouples ligand-mediated receptor activation from down-regulation
46. Role of bone marrow stromal cells in the growth of human multiple myeloma
47. Interleukin-6 in human multiple myeloma
48. p53 and RAS gene mutations in multiple myeloma